MADRID, June 20,
2024 /PRNewswire/ -- OncoBeta®, a leading medical
device company specialising in innovative epidermal radioisotope
therapies, today announced Hospital Universitario 12 de Octubre, in
Madrid, has treated its first
patient with Rhenium-SCT® (skin cancer therapy) – and is expected
to continue offering this therapy for patients with non-melanoma
skin cancers (NMSCs).
Rhenium skin cancer therapy is an advanced radionuclide therapy
technology that offers a painless,*1,2
single-session,†1-3 non-invasive‡1 treatment
without disfiguring scarring.1,4 Treatment with
Rhenium-SCT employs a superficial application of a paste containing
β-emitting particles directly to the NMSC lesion, targeting cancer
cells without the need for surgery.1,4
Shannon D. Brown III, CCO at
OncoBeta, says, "With rates of NMSC increasing globally, we feel
it's vitally important that new treatment options are offered to
patients. Surgical intervention continues to be the most common
treatment, but it can lead to disappointing results. Rhenium skin
cancer therapy addresses many patients' desires for a non-surgical
alternative – with simple application directly to the lesion,
treatment time generally ranges 45 to 180 mins, which means
patients can continue with their lives with very little
disruption."
New cases of NMSCs in Spain are
expected to almost double from 2022-2050 according to latest
figures by the International Agency of Research on Cancer as part
of the World Health Organization,5 making Mardrid an
important location for this innovative NMSC treatment option.
"Rhenium-SCT has long been accessible to patients across
Europe. This new clinic in
Spain marks a significant
milestone in expanding access to this innovative treatment for
non-melanoma skin cancer patients," Mr Brown explains.
Dr Gerhard Dahlhoff, Medical
Director at OncoBeta, says, "Rhenium-SCT allows for a targeted
and non-invasive treatment of NMSCs without damaging adjacent
healthy tissue. It offers a patient-friendly treatment alternative
and we are delighted to have another medical facility offering
Rhenium-SCT to those suffering with NMSCs."
About the Rhenium-SCT® (Skin Cancer Therapy)
Non-melanoma skin cancer (NMSC) is the most common form of cancer
in humans.1 The most common cause of NMSC is sun
exposure, while other predisposing factors include genetic skin
conditions and immunosuppressive diseases or
treatments.1,4
The Rhenium-SCT is a painless,*1,2 single
session,†1-3 non-invasive‡1 therapy that
provides aesthetic results, even in cases otherwise considered
difficult to treat.1,4,6 The Rhenium-SCT utilizes the
radioisotope rhenium-188 in an epidermal application with optimal
properties for the treatment of NMSCs (non-melanoma skin cancers).
The Rhenium-SCT is a precise, personalized therapy that is only
applied to the area needed to treat without affecting the healthy
tissue.4,6 The specially designed device ensures the
Rhenium-SCT compound never comes in direct contact with the
patient's skin and the application is safe and simple for the
applying physician. Most cases of NMSCs (basal cell carcinomas and
squamous cell carcinomas) can be treated using the Rhenium-SCT in
one single session. †1-4 Scar-free healing of the
treated lesion area and the regeneration of healthy tissue occurs
usually within a few weeks after treatment.1,6,7
About OncoBeta®
OncoBeta® with its headquarters located in Garching near
Munich, Germany, is a privately
held medical device company, specializing in the development and
commercialization of state-of-the-art, innovative therapies. Since
its foundation, OncoBeta has concentrated its efforts on the
development, regulatory approval(s) and commercialization of the
epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy),
targeting NMSCs. OncoBeta has perfected the customized application
and device management system in conformity with all health, safety,
and environmental protection regulatory standards.
Find out more about the Rhenium-SCT at www.oncobeta.com
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/oncobeta/
Instagram: https://www.instagram.com/oncobeta_gmbh/
Forward-looking statements
This announcement includes forward-looking statements that involve
risks, uncertainties and other factors, many of which are outside
of OncoBeta's control and which could cause actual results to
differ materially from the results discussed in the forward-looking
statements. Forward-looking statements include statements
concerning OncoBeta's plans, objectives, goals, future events,
performance and/or other information that is not historical
information. All such forward-looking statements are expressly
qualified by these cautionary statements and any other cautionary
statements which may accompany the forward-looking statements.
OncoBeta undertakes no obligation to publicly update or revise
forward-looking statements to reflect subsequent events or
circumstances after the date made, except as required by law.
*No reported pain during procedure.1,2
†Complete tumour regression in 98.5% of lesions
treated.3
‡A treatment is considered non-invasive when no cut or break
in the skin is created.8
References
- Castellucci P, et al. Eur J Nucl Med Mol Imaging. 2021;
48: 1511–1521.
- Cipriani C, et al. J Dermatol Treat. 2022;33(2):969–975.
Epub 22 Jul 2020.
- Cipriani C, et al. In Therapeutic Nuclear Medicine.
2014. RP Baum (Ed), New York:
Springer.
- Tietze JK, et al. Clin Nucl Med. 2023;48:869–76.
- Global Burden of Disease Cancer Collaboration, et al. JAMA
Oncol. 2019;5(12):1749-1768.
- Cipriani C, et al. International J Nucl Med. 2017;
July:114–112.
- Sedda AF, et al. Clin Exp Dermatol.
2008;33(6):745–749.
- Australian Therapeutic Goods Administration. Acronym and
glossary of terms. Available at:
https://www.tga.gov.au/resources/acronyms-and-glossary-terms.
(Accessed June 2024).
Contact:
Jane Morey
***@moreymedia.com.au
Photos
https://www.prlog.org/13025785
Press release distributed by PRLog
View original
content:https://www.prnewswire.com/news-releases/oncobeta-introduces-rhenium-sct-for-non-melanoma-skin-cancer-patients-at-hospital-universitario-12-de-octubre-302177532.html
SOURCE OncoBeta GmbH